Compare DAWN & NGVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAWN | NGVT |
|---|---|---|
| Founded | 2018 | 1964 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2021 | 2015 |
| Metric | DAWN | NGVT |
|---|---|---|
| Price | $21.42 | $70.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 2 |
| Target Price | $26.00 | ★ $72.50 |
| AVG Volume (30 Days) | ★ 6.4M | 347.0K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.10 |
| EPS | ★ N/A | N/A |
| Revenue | $158,182,000.00 | ★ $1,167,600,000.00 |
| Revenue This Year | $55.03 | $3.63 |
| Revenue Next Year | $28.12 | $0.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.60 | N/A |
| 52 Week Low | $5.64 | $28.49 |
| 52 Week High | $21.46 | $77.46 |
| Indicator | DAWN | NGVT |
|---|---|---|
| Relative Strength Index (RSI) | 81.44 | 57.22 |
| Support Level | $10.30 | $63.60 |
| Resistance Level | N/A | $77.23 |
| Average True Range (ATR) | 0.07 | 2.28 |
| MACD | -0.16 | 0.70 |
| Stochastic Oscillator | 79.55 | 85.64 |
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The Company generates the majority of its revenue from North America.